KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $115.8 million.

  • Halozyme Therapeutics' Cash & Equivalents rose 171.95% to $419.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $419.7 million, marking a year-over-year increase of 171.95%. This contributed to the annual value of $115.8 million for FY2024, which is 2.13% down from last year.
  • Halozyme Therapeutics' Cash & Equivalents amounted to $115.8 million in FY2024, which was down 2.13% from $118.4 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Cash & Equivalents registered a high of $234.2 million during FY2022, and its lowest value of $115.8 million during FY2024.
  • In the last 3 years, Halozyme Therapeutics' Cash & Equivalents had a median value of $118.4 million in 2023 and averaged $156.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 97.27% in 2022, then plummeted by 49.46% in 2023.
  • Halozyme Therapeutics' Cash & Equivalents (Yearly) stood at $147.7 million in 2020, then fell by 19.62% to $118.7 million in 2021, then skyrocketed by 97.27% to $234.2 million in 2022, then tumbled by 49.46% to $118.4 million in 2023, then dropped by 2.13% to $115.8 million in 2024.